Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 53 • 2019 ACR/ARP Annual Meeting
Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis
Agathe Leblond ¹, Sonia Pezet ¹, Anne Cauvet ¹, Claudine Casas ¹, Julie Pires Da Silva ², Roxane Herve ³, Luca Semerano ⁴, Christophe Lemaire ⁵, Yannick Allanore ⁶ and Jerome Avouac⁶, ¹INSERM U1016, Paris, France, ²Paris Sud University, Chateany Malabry, France, ³Paris 13 University, Bobigny, France, ⁴INSERM UMR 1125 , Université Paris 13, Bobigny, France, ⁵Paris Sud University, Chatenay malabry, France, ⁶Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France
Background/Purpose: To decipher the phenotype of endothelial cells (ECs) derived from circulating progenitors issued from patients with rheumatoid arthritis (RA).Methods: Proliferation capacities between RA and…
Abstract Number: 185 • 2019 ACR/ARP Annual Meeting
Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up
Kazuki Yoshida¹, Tzu-Chieh Lin ², Melissa Y Wei ³, Susan Malspeis ¹, Su H. Chu ⁴, Carlos Camargo ⁵, Benjamin A. Raby ¹, Hyon K. Choi ⁵, Sara K. Tedeschi ⁶, Medha Barbhaiya ⁷, Bing Lu ¹, Karen Costenbader ¹, Elizabeth Karlson ¹ and Jeffrey Sparks ¹, ¹Brigham and Women's Hospital, Boston, MA, ²Amgen, Thousand Oaks, CA, ³University of Michigan, Ann Arbor, MI, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Brigham and Women's Hospital, Div. of Rheumatology, Immunology and Allergy, Boston, MA, ⁷Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients often suffer from multimorbidity, the coexistence of multiple chronic morbidities. However, little is known about how multimorbidity accrues over time…
Abstract Number: 261 • 2019 ACR/ARP Annual Meeting
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh ¹, Bikramjit Bindra ² and Karan Jatwani ³, ¹St. Vincent Evansville, Evansville, ²Government Medical College & Hospital, Chandigarh, India, ³Mount Sinai West - St Luke’s Hospital, New York
Background/Purpose: Atrial Fibrillation (AF) is a common cardiac arrhythmia related to increased cardiovascular morbidity and mortality. There is a significant association of systemic inflammation with…
Abstract Number: 444 • 2019 ACR/ARP Annual Meeting
Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration
Elena Myasoedova¹, Annette De Thurah ², Marie-Line Erpelding ³, Emilce Schneeberger ⁴, Thomas Maribo ⁵, Gustavo Citera ⁶, John Davis ¹, Eric Matteson ⁷, Cynthia Crowson ⁸, Bruno Fautrel ⁹ and Francis Guillemin ³, ¹Mayo Clinic, Rochester, MN, ²Aarhus University Hospital, Aarhus, Denmark, ³Inserm, University of Lorraine, Nancy, France, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵DEFACTUM, Aarhus, ⁶Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, ⁷Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁸Mayo Clinic Rochester, Rochester, ⁹Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France
Background/Purpose: Flares are inherent to the rheumatoid arthritis (RA) disease course and associated with poor clinical outcomes including low quality of life, joint damage and…
Abstract Number: 469 • 2019 ACR/ARP Annual Meeting
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Susumu Nishiyama¹, Tetsuji Sawada ² and Shigeto Tohma ³, ¹Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan, ²Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan, ³National Hospital Organization Tokyo National Hospital, Tokyo, Japan
Background/Purpose: To predict prognosis of patients with rheumatoid arthritis (RA) from the location and the size of affected joints.Methods: Data of 7,776 patients with RA,…
Abstract Number: 506 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Bernard Combe¹, Alan Kivitz ², Yoshiya Tanaka ³, Désirée van der Heijde ⁴, Franziska Matzkies ⁵, Beatrix Bartok ⁵, Lei Ye ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Robert B.M. Landewé ⁷, Sang-Cheol Bae ⁸, Edward Keystone ⁹ and Peter Nash ¹⁰, ¹CHU Montpellier, Montpellier University, Montpellier, France, ²Altoona Center for Clinical Research, Duncansville, PA, ³University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands, ⁸Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹⁰University of Queensland, Brisbane, Queensland, Australia
Background/Purpose: Filgotinib (FIL) is an orally administered, potent and selective inhibitor of Janus kinase 1 (JAK1) that has shown good efficacy and was well tolerated…
Abstract Number: 641 • 2019 ACR/ARP Annual Meeting
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Anders Bengtsson ¹, Helena Tyden ¹, Tiffany Pan ², J. Lee Nelson ³ and Christian Lood², ¹Lund University, Lund, Sweden, ²University of Washington, Seattle, ³Fred Hutchinson Cancer Research Center, Seattle
Background/Purpose: Circulating immune complexes (IC) are detectable in a variety of systemic inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), reflecting the…
Abstract Number: 924 • 2019 ACR/ARP Annual Meeting
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth ¹, Elizabeth Hernandez ² and Matthew Budoff ¹, ¹Harbor-UCLA Medical Center and Los Angeles Biomedical Institute, Torrance, CA, ²Harbor-UCLA Medical center and Los Angeles Biomedical Research Institute, Torrance
Background/Purpose: We recently reported that highly-sensitive cardiac troponin-I (hs-cTnI) associates with occult coronary atherosclerosis burden and cardiovascular event (CVE) risk in rheumatoid arthritis (RA). We…
Abstract Number: 1123 • 2019 ACR/ARP Annual Meeting
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Maria Schletzbaum¹, Xing Wang ¹, Robert Greenlee ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Marshfield Clinic Research Institute, Marshfield, WI
Background/Purpose: Smoking doubles the risk of developing RA, and continuing to smoke after RA diagnosis is associated with worse disease control, treatment failure, and premature…
Abstract Number: 1333 • 2019 ACR/ARP Annual Meeting
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea
Eun Hye Park¹, Anna Shin ², Yaa-Hui Dong ³, You-Jung Ha ¹, Yun Jong Lee ⁴, Eun Bong Lee ⁵, Yeong-Wook Song ⁶ and Eun Ha Kang ¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ²Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ³Graduate Institute of Epidemiology and Preventive Medicine, National Taiwan University, Taipei, Taiwan (Republic of China), ⁴Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea, Seongnam, Republic of Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, seoul, ⁶Seoul National University Hospital, Seoul, Republic of Korea
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increased risk of osteoporosis and osteoporotic fracture, but little is known about comparative risk of osteoporotic fractures between…
Abstract Number: 1358 • 2019 ACR/ARP Annual Meeting
Defining Minimal Clinically Important Changes for the Patient Activity Scale-II
Joshua Baker¹, Patricia Katz ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²University of California, San Francisco, san francisco, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Patient Activity Scale (PAS)-II is an accepted disease activity measure used in the care of patients with rheumatoid arthritis (RA). A clinically important…
Abstract Number: 1386 • 2019 ACR/ARP Annual Meeting
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Leslie Harrold¹, Ying Shan ², Sabrina Rebello ², Lin Guo ², Sean Connolly ³, Joe Zhuo ³, Sheila Kelly ³ and Thomas Lehman ³, ¹University of Massachusetts and Corrona, LLC, Waltham, MA, ²Corrona, LLC, Waltham, MA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: In a US national observational study conducted in a clinical practice setting, patients who were positive (+) for anti-cyclic citrullinated peptide (CCP) antibodies at…
Abstract Number: 1418 • 2019 ACR/ARP Annual Meeting
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous- Golimumab in a Prospective, Observational Registry
Proton Rahman ¹, Rafat Faraawi ², Louis Bessette ³, Andrew Chow ⁴, Jodie Reis ⁵, Keltie Anderson ⁵, Emmanouil Rampakakis ⁶, Meagan Rachich ⁷, Odalis Asin-Milan ⁷, Allen Lehman ⁷ and Francois Nantel⁷, ¹Memorial University, Newfoundland, NL, Canada, ²McMaster University, Hamilton, ON, Canada, ³Laval University, Laval, QC, Canada, ⁴Credit Valley Rheumatology, Mississauga, ON, Canada, ⁵University of Saskatchewan, Saskatoon, SK, Canada, ⁶JSS Medical Research, Montreal, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: The Biologic Treatment Registry Across Canada (BioTRAC) was a prospective, observational registry that enrolled rheumatoid arthritis (RA) patients treated with either subcutaneous golimumab (GLM-SC)…
Abstract Number: 1801 • 2019 ACR/ARP Annual Meeting
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Vardhaman Patel¹, Zulkarnain Pulungan ², Anne Shah ², Mahesh Kambhampati ², Francis Lobo ³ and Allison Petrilla ², ¹Bristol-Myers Squibb, New York City, NY, ²Avalere, washington, DC, ³Bristol-Myers Squibb Company, Princeton, NJ
Background/Purpose: The risk and cost of infection-related hospitalizations in tumor necrosis factor inhibitors (TNFi)-experienced patients with rheumatoid arthritis (RA) receiving subsequent targeted disease-modifying antirheumatic drug…
Abstract Number: 1928 • 2019 ACR/ARP Annual Meeting
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Antonio Julià¹, Maria Lopez Lasanta ², Antonio Gómez ³, Irene Bonafonte ⁴, Raimon Sanmartí ⁵, Carlos Marras ⁶, José Manuel Pina ⁷, Susana Romero-Yuste ⁸, Raul Veiga ⁹, Pilar Navarro ⁹, Carmen Moragues Pastor ¹⁰, Silvia Martínez ¹¹, Francisco J. De Toro ¹², Amalia Sanchez ¹³, Dacia Cerdà ¹⁴, Alejandro Prada ¹⁵, Alba Erra ¹⁶, Jordi Monfort ¹⁷, A. Urruticoechea-Arana ¹⁸, Núria Palau ¹⁹, Raquel Lastra ²⁰, Raúl Tortosa ³, Andrea Pluma ²¹ and Sara Marsal ²², ¹Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ²Hospital Universitari Vall Hebrón, Barcelona, Barcelona, Catalonia, Spain, ³Hospital Vall d'Hebron, Barcelona, Barcelona, Spain, ⁴Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁵Hospital Clínic, Barcelona, Barcelona, Spain, ⁶Hospital Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁷Hospital de Barbastro, Huesca, Barbastro, Huesca, Spain, ⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ⁹Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ¹⁰Platò Hospital, Barcelona, Spain, Barcelona, Spain, ¹¹Hospital Universitari Mútua Terrassa, Terrassa, Spain, ¹²University Hospital A Coruña, A Coruña, Spain, ¹³Hospital Universitario Lucus Augusti, Lugo, Lugo, Spain, ¹⁴Hospital Moisès Broggi, Sant Joan Despí, Sant Joan Despí, Spain, ¹⁵Hospital Universitario Torrejón de Ardoz, Torrejón de Ardoz, Spain, ¹⁶Hospital Sant Rafael, Barcelona, Barcelona, Spain, ¹⁷Hospital del Mar, Barcelona, Spain, ¹⁸HU Can Misses, Ibiza, Spain, ¹⁹Hospital Vall Hebrón Barcelona, Barcelona, Spain, ²⁰Hospital Vall Hebron, Barcelona, Barcelona, Spain, ²¹Hospital Universitari Vall d'Hebron, Barcelona, Spain, ²²Vall d’Hebron Hospital, Barcelona, Catalonia, Spain
Background/Purpose: Abatacept (CTLA4-Ig) is an approved biological therapy for the treatment of rheumatoid arthritis (RA). Similar to other biological agents, most patients (50-60%) respond significantly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].